Therapeutics News and Research

RSS

CSL Behring awarded NHF's 2015 Corporate Leadership Award

The National Hemophilia Foundation has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company's longstanding and unwavering commitment to advancing science and improving the care of the bleeding disorders community. The award was accepted by Paul Perreault, CEO and Managing Director, CSL Limited, during the NHF Annual Spring Soiree in New York City on May 21.

24 May 2015

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%.

22 May 2015

LSDF awards $2.9 million in funding to help commercialize major medical breakthroughs

Celiac disease-safe wheat, premature infant pain detection, and new medicines to fight flu and cancer are among the ideas to receive $2.9 million in funding from Washington's Life Sciences Discovery Fund (LSDF).

22 May 2015

Chemical compound shows promise in treating rheumatoid arthritis

Montana State University researchers and their collaborators have published their findings about a chemical compound that shows potential for treating rheumatoid arthritis.

22 May 2015

UH pharmacy students receive awards for excellence in clinical skills, disease management

University of Houston pharmacy students wrapped up the spring semester with awards for excellence in professional service, clinical skills and disease management, earning kudos at the state level from the Texas Society of Health-System Pharmacists.

22 May 2015

Enterprise Therapeutics secures additional funding to accelerate drug discovery for treatment of respiratory diseases

ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured an additional £2.4m ($3.6m) in Series-A financing.

21 May 2015

Second-generation antibiotic shows promise against common bacterial infections

Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults.

21 May 2015

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer.

21 May 2015

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Merus and Selexis will combine their unique and proprietary Oligoclonics® and SUREtechnology™ platforms respectively to develop a product combining two bispecific full length IgG antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases...

20 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, the bacteria responsible for the chronic lung infection tuberculosis.

19 May 2015

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

vTv Therapeutics LLC today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease.

19 May 2015

U.K Ophthalmologists lead in treatment of wet AMD patients with Oraya therapy across europe

Oraya Therapy was introduced first in the U.K., followed by Switzerland and Germany. The therapy is intended as a one-time, non-invasive treatment that maintains vision with fewer anti-vascular endothelial growth factor (anti-VEGF) injections into the eye...

19 May 2015

Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Cryoport, Inc. today announced financial results for the three and twelve-month periods ended March 31, 2015.

19 May 2015

New microfluidic chip can capture rare clusters of circulating tumor cells

Researchers have developed a microfluidic chip that can capture rare clusters of circulating tumor cells, which could yield important new insights into how cancer spreads. The work was funded by the National Institute of Biomedical Imaging and Bioengineering, part of the National Institutes of Health.

19 May 2015

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

Researchers uncover major link between human body clock and immune system

An important link between the human body clock and the immune system has relevance for better understanding inflammatory and infectious diseases, discovered collaborators at the Perelman School of Medicine at the University of Pennsylvania and Trinity College, Dublin.

19 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals Inc. announced financial results for the first quarter ended March 31, 2015. Immune filed its Quarterly Report on Form 10-Q for the first quarter of 2015 on Friday, May 15, 2015.

18 May 2015

New findings could help better understand neurodegenerative diseases

Researchers at the Luxembourg Centre for Systems Biomedicine (LCSB), of the University of Luxembourg, have, under Dr. Manuel Buttini, successfully measured metabolic profiles, or the metabolomes, of different brain regions, and their findings could help better understand neurodegenerative diseases.

18 May 2015

Therapeutics News and Research

CSL Behring awarded NHF's 2015 Corporate Leadership Award

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

LSDF awards $2.9 million in funding to help commercialize major medical breakthroughs

Chemical compound shows promise in treating rheumatoid arthritis

UH pharmacy students receive awards for excellence in clinical skills, disease management

Enterprise Therapeutics secures additional funding to accelerate drug discovery for treatment of respiratory diseases

Second-generation antibiotic shows promise against common bacterial infections

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

U.K Ophthalmologists lead in treatment of wet AMD patients with Oraya therapy across europe

Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

New microfluidic chip can capture rare clusters of circulating tumor cells

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

Researchers uncover major link between human body clock and immune system

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

New findings could help better understand neurodegenerative diseases

Advancing therapeutic biopolymer development eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News